MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology _ Genomics, Genetic Testing, Gene & DNA Sequencing, NGS (Next Generation Sequencing) Companies
Sequenta
Attachments
index.jhtml
Parents
*Architects: Biotechnology _ Genomics, Genetic Testing, Gene & DNA Sequencing, NGS (Next Generation Sequencing) Companies
*Industry: San Francisco, California
Experienced Leadership and/or Investment Team with Winning Past Performance
Children
Betty Diamond of The Feinstein Institute for Medical Research
David Grainger of Cambridge University.
Doing this kind of immune-system sequencing was impossible just a few years ago, as it would have cost a few million dollars with traditional sequencing to examine immune cell diversity in just a milliliter of blood
Each assay the company develops could have multiple applications, rather than just one like some other molecular diagnostic companies
Now this kind of specific sequencing of immune cells can be done for about $100, making it possible to start a company devoted to using it as tool for diagnosing disease
Rob Holt of the University of British Columbia
Ron Levy, Ron Davis, and Larry Steinman of Stanford University
Rowan Chapman of Mohr Davidow
San Francisco, California
Secured $13 million in a Series B venture round that included Mohr Davidow Ventures, Index Ventures, and individual investor Jacob Goldfield, the former chief investment officer of Soros Fund Management
Sequenta Pockets $13M To Diagnose, Monitor Immune Systems Going Awry(2010)
Sequenta, which has now raised a total of $15 million, was co-founded by Tom Willis and Malek Fahem.
The idea at Sequenta is to gather a new kind of information for physicians about whether a patient’s immune system has gone out of whack.
Those two entrepreneurs previously co-founded ParAllele Bioscience, a company that was backed by Mohr Davidow and ultimately sold to Santa Clara, CA-based Affymetrix (NASDAQ: AFFX) for more than $130 million
Jumps
Illumina, Inc. (NASDAQ: ILMN)